课题基金 / 基金详情

Development of novel therapeutics for the treatment of the genetic disorder Spinal Muscular Atrophy

Development of novel therapeutics for the treatment of the genetic disorder Spinal Muscular Atrophy
开发治疗遗传性疾病脊髓性肌萎缩症的新疗法
批准号:
304815
负责人:
Parks Robin J
金额:
$52.04万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2014
资助国家:
加拿大
项目状态:
已结题
起止时间:
2014-03-01 至 2019-03-01

项目摘要

项目成果

Parks Robin J的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Spinal muscular atrophy (SMA) is a devastating disorder primarily affecting newborns and young children. It is caused by reduced levels of the survival motor neuron (SMN) protein. Although normally expressed in all cells of the body, reduced expression of
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
6th Ottawa International Conference on Neuromuscular Disease and Biology
  • 批准号:
    480782
  • 项目类别:
    Miscellaneous Programs
  • 资助金额:
    $1.09万
  • 财政年份:
    2023
  • 负责人:
    Parks Robin J
  • 依托单位:
Epigenetic Regulation of the Adenovirus Genome
  • 批准号:
    468931
  • 项目类别:
    Operating Grants
  • 资助金额:
    $50.71万
  • 财政年份:
    2022
  • 负责人:
    Parks Robin J
  • 依托单位:
Extracellular vesicles as a biomarker and therapeutic for Spinal Muscular Atrophy
  • 批准号:
    443250
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.94万
  • 财政年份:
    2021
  • 负责人:
    Parks Robin J
  • 依托单位:
Extracellular vesicles as a biomarker and therapeutic for Spinal Muscular Atrophy
  • 批准号:
    442958
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2020
  • 负责人:
    Parks Robin J
  • 依托单位:
海外基金